See every side of every news story
Published loading...Updated

Avertix Guardian System Evaluated for Cost-Effectiveness in ACS Patients - Cardiac Interventions Today

Summary by Cardiac Interventions Today
February 18, 2025—Avertix Medical, Inc. recently announced new data confirming the cost-effectiveness of the company’s Guardian system in high-risk acute coronary syndrome (ACS) patients. The Guardian system is a real-time, continuous heart attack detection and patient alerting system. The analysis leveraged data from the pivotal ALERTS clinical trial and was complemented by findings from relevant literature, noted Avertix. According to the comp…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Cardiac Interventions Today broke the news in on Tuesday, February 18, 2025.
Sources are mostly out of (0)